AR072818A1 - Derivados de pirimidin-azetidin sulfonamidas,composiciones farmaceuticas que los contienen,proceso de preparacion de los mismos e intermediarios de dicho proceso, y uso de los mismos para tratar enfermedades inflamatorias e inmunologicas tales como asma, rinitis alergica y artrosis, entre otras. - Google Patents

Derivados de pirimidin-azetidin sulfonamidas,composiciones farmaceuticas que los contienen,proceso de preparacion de los mismos e intermediarios de dicho proceso, y uso de los mismos para tratar enfermedades inflamatorias e inmunologicas tales como asma, rinitis alergica y artrosis, entre otras.

Info

Publication number
AR072818A1
AR072818A1 ARP090102722A ARP090102722A AR072818A1 AR 072818 A1 AR072818 A1 AR 072818A1 AR P090102722 A ARP090102722 A AR P090102722A AR P090102722 A ARP090102722 A AR P090102722A AR 072818 A1 AR072818 A1 AR 072818A1
Authority
AR
Argentina
Prior art keywords
arthrosis
azetidin
sulfonamides
immunological
asthma
Prior art date
Application number
ARP090102722A
Other languages
English (en)
Inventor
Jeffrey Paul Stonehouse
Premji Meghani
Andrew James Robbins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR072818A1 publication Critical patent/AR072818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de formula (1) y sales farmacéuticamente aceptables de este para usar en el tratamiento de enfermedades y afecciones mediadas por quimiocina. Reivindicacion 14: Un compuesto como se reivindica en la reivindicacion 1 o una sal farmacéuticamente aceptable caracterizado porque es en cualquiera de las siguientes formas cristalinas: (a) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 3 en la presente, nombrada modificacion A; (b) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 4 anteriormente en la presente, nombrada modificacion B; (c) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 5 en la presente, nombrada modificacion C; (d) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 6 en la presente, nombrada modificacion D; (e) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 7 en la presente, nombrada modificacion E; o (f) como la caracterizada mediante un patron de difraccion de rayos X en polvo (DRXP) como el que se muestra en la Tabla 8 en la presente, nombrada modificacion F.
ARP090102722A 2008-07-16 2009-07-16 Derivados de pirimidin-azetidin sulfonamidas,composiciones farmaceuticas que los contienen,proceso de preparacion de los mismos e intermediarios de dicho proceso, y uso de los mismos para tratar enfermedades inflamatorias e inmunologicas tales como asma, rinitis alergica y artrosis, entre otras. AR072818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8121308P 2008-07-16 2008-07-16

Publications (1)

Publication Number Publication Date
AR072818A1 true AR072818A1 (es) 2010-09-22

Family

ID=41011976

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102722A AR072818A1 (es) 2008-07-16 2009-07-16 Derivados de pirimidin-azetidin sulfonamidas,composiciones farmaceuticas que los contienen,proceso de preparacion de los mismos e intermediarios de dicho proceso, y uso de los mismos para tratar enfermedades inflamatorias e inmunologicas tales como asma, rinitis alergica y artrosis, entre otras.

Country Status (13)

Country Link
US (1) US20100016275A1 (es)
EP (1) EP2315754A1 (es)
JP (1) JP2011528030A (es)
KR (1) KR20110031462A (es)
CN (1) CN102159555A (es)
AR (1) AR072818A1 (es)
AU (1) AU2009272425B2 (es)
BR (1) BRPI0915908A2 (es)
CA (1) CA2730477A1 (es)
MX (1) MX2011000402A (es)
RU (1) RU2011101661A (es)
TW (1) TW201006824A (es)
WO (1) WO2010007427A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809624B1 (en) * 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
MY167869A (en) 2010-07-13 2018-09-26 Astrazeneca Ab New Crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R, 2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MY180039A (en) * 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
JP6096808B2 (ja) * 2012-02-07 2017-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なアゼチジン誘導体
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
AU2017231832B2 (en) 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540356A (en) * 1949-03-12 1951-02-06 Sharp & Dohme Inc Sulfonamide derivatives
GB866843A (en) * 1958-12-08 1961-05-03 Ici Ltd Sulphonamidopyrimidines
NL279406A (es) * 1961-06-16
NL127990C (es) * 1962-12-29
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
US3452018A (en) * 1966-08-29 1969-06-24 American Home Prod 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
DE60318219T2 (de) * 2002-08-24 2009-01-15 Astrazeneca Ab PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
EP1809624B1 (en) * 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
JP2006137723A (ja) * 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体

Also Published As

Publication number Publication date
CA2730477A1 (en) 2010-01-21
AU2009272425B2 (en) 2012-02-02
BRPI0915908A2 (pt) 2018-07-10
US20100016275A1 (en) 2010-01-21
MX2011000402A (es) 2011-03-15
TW201006824A (en) 2010-02-16
WO2010007427A1 (en) 2010-01-21
CN102159555A (zh) 2011-08-17
RU2011101661A (ru) 2012-08-27
KR20110031462A (ko) 2011-03-28
AU2009272425A1 (en) 2010-01-21
JP2011528030A (ja) 2011-11-10
EP2315754A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
AR072818A1 (es) Derivados de pirimidin-azetidin sulfonamidas,composiciones farmaceuticas que los contienen,proceso de preparacion de los mismos e intermediarios de dicho proceso, y uso de los mismos para tratar enfermedades inflamatorias e inmunologicas tales como asma, rinitis alergica y artrosis, entre otras.
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
CU20140068A7 (es) Triazolopiridinas sustituidas
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
NI201200172A (es) Activadores de guanilato ciclasa soluble
AR085039A1 (es) DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201100137A (es) Derivados de sulfonamida
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
ECSP13013011A (es) Triazolopiridinas
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
CU20120171A7 (es) Triazolopiridinas sustituidas
CO6290670A2 (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
UY33191A (es) Derivados de pirazina
AR093408A1 (es) Derivados de oxazolidin-2-ona-pirimidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure